Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
Source: View publication →
In patients with resectable gastric or gastroesophageal junction adenocarcinoma, the addition of perioperative durvalumab to standard FLOT chemotherapy significantly improved event-free survival compared with chemotherapy alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The MATTERHORN trial establishes a new standard of care for patients with early-stage, resectable gastric and gastroesophageal junction adenocarcinoma. By demonstrating that the addition of the PD-L1 inhibitor durvalumab to perioperative FLOT chemotherapy yields a statistically significant and clinically meaningful improvement in event-free survival, the study validates the integration of immunotherapy into the curative-intent setting for these high-risk malignancies.
Historical Context
Historically, the landmark FLOT4 trial established perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) as the standard of care for resectable gastric and gastroesophageal junction cancers, offering improved survival over older anthracycline-based regimens. However, despite optimal surgery and chemotherapy, recurrence rates remained frustratingly high. Concurrently, immune checkpoint inhibitors revolutionized the management of advanced/metastatic gastrointestinal cancers, as demonstrated in trials like CheckMate-649 (nivolumab) and KEYNOTE-859 (pembrolizumab). The phase 3 MATTERHORN trial was designed to bridge this gap, testing whether introducing PD-L1 blockade earlier into the perioperative, curative-intent setting could effectively reduce recurrences and improve long-term outcomes.
Guided Discussion
High-yield insights from every perspective
What is the mechanism of action of durvalumab, and why is it theoretically synergistic with the FLOT chemotherapy regimen in the treatment of resectable gastric adenocarcinoma?
Key Response
Durvalumab is a monoclonal antibody that blocks PD-L1, preventing it from binding to PD-1 and CD80, thereby releasing T-cell suppression. FLOT chemotherapy induces immunogenic cell death, releasing tumor neoantigens and upregulating inflammatory pathways, which primes the tumor microenvironment for enhanced T-cell activation when immune checkpoint inhibition is applied.
When managing a patient receiving perioperative durvalumab and FLOT, what are the components of the FLOT regimen, and how does the addition of immunotherapy alter the expected perioperative toxicity profile and surgical timing?
Key Response
FLOT comprises 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel. While the MATTERHORN trial showed similar rates of surgical complications, the addition of durvalumab introduces the risk of immune-related adverse events (irAEs) like pneumonitis, colitis, or endocrinopathies, which require high vigilance as they can complicate surgical recovery or delay the planned resection.
The MATTERHORN trial demonstrated an event-free survival benefit with the addition of durvalumab. How does a patient's mismatch repair (MMR) status and PD-L1 Combined Positive Score (CPS) influence the expected magnitude of benefit from this regimen, and how do these findings contrast with the recent KEYNOTE-585 trial?
Key Response
Patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumors typically derive the most profound benefit from immune checkpoint inhibitors. Evaluating if PD-L1 CPS cutoffs dictate efficacy remains debated, especially since KEYNOTE-585 (pembrolizumab plus FLOT) failed to meet its primary EFS endpoint, raising questions about trial design differences, drug-specific effects, and optimal patient selection.
Although the MATTERHORN trial met its primary endpoint of event-free survival, overall survival data remains immature. Given this, how should clinicians counsel a fit patient with newly diagnosed resectable gastric cancer about incorporating durvalumab into their FLOT regimen, particularly regarding the risk of long-term immune toxicities versus uncertain survival benefit?
Key Response
In gastrointestinal oncology, EFS and pathologic complete response (pCR) are strong surrogates but do not always translate to an overall survival (OS) benefit. Attendings must balance the proven early surrogate benefits against the permanent risks of immunotherapy (e.g., lifelong adrenal insufficiency or hypothyroidism) and discuss these trade-offs transparently until mature OS data is available.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In the MATTERHORN trial design, event-free survival (EFS) was chosen as the primary endpoint. From a methodological standpoint, how does the inclusion of 'progression precluding surgery' in the EFS definition impact statistical power and the interpretation of the results compared to traditional disease-free survival (DFS)?
Key Response
EFS captures events that occur before surgery, such as disease progression during neoadjuvant therapy or failure to reach resection, which DFS misses (as DFS only applies to patients who undergo surgery). Capturing these early events provides a more comprehensive measure of neoadjuvant efficacy and increases early event rates, boosting statistical power, though it complicates direct comparisons with older adjuvant-focused trials.
As a peer reviewer evaluating the MATTERHORN manuscript, what critical scrutiny must be applied to the geographical distribution of the enrolled patients, specifically regarding regional variations in surgical techniques like D2 lymphadenectomy and baseline tumor biology?
Key Response
Gastric cancer biology and surgical standards vary significantly by region; for instance, Asian centers traditionally perform more extensive D2 lymphadenectomies and see higher rates of distal tumors compared to Western centers. A seasoned reviewer would flag whether the survival benefit of durvalumab is consistent across these regions, as imbalances in surgical quality could confound generalizability.
NCCN and ESMO guidelines currently recommend perioperative FLOT as a preferred standard for resectable gastric and GEJ adenocarcinoma. Based on the MATTERHORN data, should the guidelines be updated to universally recommend the addition of durvalumab, or should its use be restricted based on specific biomarkers like MSI status or PD-L1 CPS?
Key Response
While the addition of durvalumab improves EFS, updating guidelines to a universal strong recommendation typically requires mature Overall Survival (OS) data. Committee members must debate whether to issue a category 2A recommendation for the overall population based on EFS and pCR improvements, while possibly making a stronger recommendation for the dMMR/MSI-H subgroup where immunotherapy has a well-established, outsized benefit.
Clinical Landscape
Noteworthy Related Trials
FLOT4-AIO Trial
Tested
Perioperative FLOT chemotherapy
Population
Patients with resectable gastric or GEJ cancer
Comparator
Perioperative ECF or ECX chemotherapy
Endpoint
Overall survival
CheckMate 577
Tested
Adjuvant nivolumab
Population
Patients with resected esophageal or GEJ cancer after neoadjuvant chemoradiotherapy
Comparator
Placebo
Endpoint
Disease-free survival
KEYNOTE-585 Trial
Tested
Perioperative pembrolizumab plus chemotherapy
Population
Patients with locally advanced resectable gastric or GEJ cancer
Comparator
Placebo plus chemotherapy
Endpoint
Event-free survival and pathological complete response
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis